Eli Lilly Confronts Compounding Safety Concerns Ahead of Pivotal Oral Drug Decision

Pharmaceutical giant Eli Lilly issued a significant public safety alert on March 12, 2026, concerning chemically contaminated compounded versions of its weight-loss medication, tirzepatide. This move comes at a critical juncture for the company, which faces a landmark FDA verdict on its oral GLP-1 candidate, orforglipron, by April 10, 2026. The timing underscores the intense pressure to safeguard its multi-billion dollar franchise.

Protecting a Market-Leading Franchise

The safety warning specifically targets tirzepatide formulations that compounding pharmacies have been mixing with vitamin B12. Company testing revealed substantial quantities of a chemical impurity resulting from the reaction between the two substances. No data currently exists on the short- or long-term effects of this compound on the human body, including its potential toxicity or interaction with GLP-1 and GIP receptors.

Lilly has notified the U.S. Food and Drug Administration (FDA) of its findings and is calling for a recall of all compounded tirzepatide products containing such untested additives. While B12 is one example, compounders have also been blending the drug with substances like glycine, pyridoxine, niacinamide, and carnitine—all without regulatory review.

This situation stems from a regulatory shift. In October 2024, the FDA declared an end to the tirzepatide shortage that had initially justified the compounding exception. Since then, some suppliers have attempted to justify their products through minor dosage adjustments or the addition of supplements, a practice Lilly views as a circumvention of the law.

The commercial stakes are enormous. In 2025, tirzepatide—marketed as Mounjaro and Zepbound—generated combined global revenue of $36.51 billion, surpassing the $31.7 billion earned by Merck’s blockbuster cancer drug, Keytruda.

Should investors sell immediately? Or is it worth buying Eli Lilly?

The Race for an Oral GLP-1 Therapy Intensifies

Amid the compounding dispute, Lilly is approaching a decisive milestone. The Prescription Drug User Fee Act (PDUFA) date for its oral GLP-1 candidate, orforglipron, is set for April 10, 2026. This drug holds a potential advantage over Novo Nordisk’s already-approved oral semaglutid: it can be taken without food restrictions, whereas Novo’s pill must be taken on an empty stomach.

Novo Nordisk’s oral Wegovy gained U.S. approval in December 2025 and became available in over 70,000 pharmacies by early January 2026. Therefore, an approval for orforglipron would see Lilly entering a market where its main competitor is already established.

Clinical evidence from the ATTAIN program supports the drug’s efficacy. In two Phase 3 trials—one involving non-diabetic patients and another with Type 2 diabetes patients—orforglipron demonstrated statistically significant weight reduction compared to a placebo. A third study further showed the medication was more effective than a placebo at maintaining weight loss in patients previously treated with injectable semaglutide or tirzepatide.

Lilly has already initiated global regulatory submissions and made production investments across several U.S. states. The company is targeting total revenue of $83 billion for 2026. A favorable FDA decision on April 10 would position Lilly with both injectable and oral GLP-1 options for the first time, enabling it to compete with Novo Nordisk across all major administration routes.